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Abstract
Introduction. Nowadays heart failure (HF) presents an enormous and rapidly growing public health problem. HF is cha-
racterized by high morbidity and mortality and high costs.
Material and methods. The analysis included medical records of 100 consecutive patients with HF treated in the De-
partment of Cardiology during the first quarter of 2015.
Results. The mean age of the whole investigated population was 73 years (63% males). The most prevalent concomitant 
diseases were: arterial hypertension (58%), coronary artery disease (46%), the presence of moderate or severe mitral 
or aortic valvular defect (34%), atrial fibrillation (38%), and diabetes mellitus (29%).
Conclusions. Data from hospitalized HF registries are useful to better understand the clinical characteristics, patient 
management and outcomes after discharge.
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Introduction
Heart failure (HF) is a major public health problem. It is 
estimated that the prevalence of HF is 1–2% in the general 
population and as high as 10% in patients over 70 years 
of age [1]. Rapid increase in the number of patients with 
HF is a consequence of both the aging of society and the 
development of interventional cardiology and electrothera-
py. Currently, the most common causes of HF are ischemic 
heart disease and hypertension. HF is associated with very 
poor prognosis and 5-year survival rates are worse than 
for most cancers [2].
The aim of this study was to present the clinical profile 
of patients hospitalized for heart failure in the cardiology 
department of a multi-specialty district hospital in Poland.
Material and methods
Medical records of 10,925 patients hospitalized at the 
Western Hospital in Grodzisk Mazowiecki, Poland in the 
first quarter of 2015 were analyzed retrospectively. Of this 
group, the authors selected medical records of 100 conse-
cutive patients hospitalized in the cardiology department in 
whom HF was indicated in the hospital discharge summary 
as a primary diagnosis.
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Clinical characteristics of patients
Among the selected patients, the median age was 73 years. 
In this population, males accounted for 63% of the patients, 
were younger and had lower comorbidity burden compared 
with hospitalized women. Nearly one third of the patients 
were admitted in an urgent mode based on the decision by 
the Emergency Medical Service team; 64% of the patients 
reported the New York Heart Association (NYHA) class III or 
IV symptoms at admission. The most common concomitant 
disease was hypertension, which affected 64% of the pa-
tients. Supraventricular arrhythmias, i.e. atrial fibrillation 
or flutter, occurred in 38% of the patients, and 46% had 
coronary artery disease. The most common valvular heart 
defect was mitral regurgitation, which was almost 6 times 
more frequent than aortic stenosis (mild valvular heart 
defects in echocardiographic evaluation were disregarded). 
Mean levels of N-terminal B-type natriuretic propeptide 
(NT-proBNP) and sodium were 4819 ± 6968 pg/mL and 
138 ± 4 mmol/L, accordingly. Most patients had impaired 
renal function, defined as glomerular filtration rate (GFR) 
less than 50 mL/min/1.73 m2, and 17% had stage 4/5 
chronic renal disease. Thirty-one percent of the patients 
had left ventricular ejection fraction (LVEF) ≥ 50%. Forty-
-two percent of the patients had left ventricular systolic 
dysfunction of various degrees, of which 2/3 had an LVEF 
less than 40%. Twenty-eight percent of the patients did 
not undergo echocardiographic evaluation of LVEF during 
hospitalization (Table 1).
Discussion
It is estimated that the number of patients with HF in Po-
land is 600–700 thousand and that every fifth person will 
develop HF at some point of his/her life [2]. Medical care 
for patients with HF both in outpatient setting and during 
frequent hospitalizations due to HF exacerbation, which 
are typical of the natural course of the disease, cause 
considerable social and financial burden.
Our analysis included patients hospitalized in the cardio-
logy department of a multi-specialty district hospital, where 
there is also a department of internal diseases. The decision 
about the destination of the patient (a department of car-
diology vs. department of internal diseases) is taken during 
his/her stay at the Hospital Emergency Department, usually 
after prior cardiac consultation. This allows for identification 
of patients who require specialist treatment (Table 2).
The mean age of patients hospitalized due to HF in 
Poland is consistent with the age of patients participating 
in large registry trials in developed countries such as Ja-
pan (ATTEND) [3], France (EFICA) [4] or USA (ADHERE [5], 
OPTIMIZE-HF [6]).
Table 1. Clinical characteristics of patients
Parameter Value
Age 73 years
Male 63%
Mode of admission to hospital:
• arrival by ambulance
• own or public transport
28%
72%
Symptoms in III/IV NYHA class 68%
Hypertension 58%
History of myocardial infarction
PCI
CABG
24%
18%
4%
AF/AFL 38%
Mitral insufficiency
Aortal stenosis
29%
5%
COPD 16%
Type 2 diabetes 29%
Pacemaker 2%
ICD 7%
CRT 3%
Stroke/TIA 7%
BMI [kg/m2]:
• < 18.5
• 18.5–24.99
• 25–29.99
• ≥ 30
20%
10%
33%
35%
NT-proBNP [pg/mL] 4819
Hb [g/dL] 12.79
Na [mmol/L] 137.7
GFR [mL/min/1.73 m2]:
• < 30
• 30–49
• > 50
17%
71%
12%
LVEF:
• < 40%
• 40–49%
• ≥ 50% 
27%
15%
31%
NYHA — New York Heart Association; PCI — percutaneous coronary intervention; CABG — coronary 
artery bypass grafting; AF — atrial fibrillation; AFL — atrial flutter; COPD — chronic obstructive 
pulmonary disease; ICD — implantable cardioverter-defibrillator; CRT — cardiac resynchronization 
therapy; TIA — transient ischemic attack; BMI — body mass index; NT-proBNP — N-terminal B-type 
natriuretic propeptide; Hb — hemoglobin; Na — sodium; GFR — glomerular filtration rate; LVEF — left  
ventricular ejection fraction
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As in most European registries, such as ESC-HF Pilot 
[7], EHFS II [8], IN-HF [9], also in our study the majority of 
hospitalized patients (63%) were males. Women are tra-
ditionally less represented, not only in randomized clinical 
trials on HF but also in hospital registries. There is, however, 
one exception — available data indicate higher proportion 
of women requiring hospitalization due to HF only in the 
United States, which is contrary not only to data obtained 
in Europe but also in other regions of the world.
It is also worth noting that, as shown in the Western 
Hospital registry, women at the time of diagnosis of HF were 
older than men and were more likely to have heart failure 
with preserved ejection fraction (HFpEF).
The lower prevalence of coronary heart disease ob-
served in our study (46% vs 50–57% in other registries) 
may be due to a slightly different questionnaire developed 
to describe a population in which coronary artery disease 
was diagnosed solely based on a history of myocardial 
infarction, prior coronary revascularization or coronary 
angiography. However, when taking into account the pro-
portion of patients with HF and a history of myocardial 
infarction, the differences are much lower — 24% vs. 22% 
in the French registry or 31% in the US registry.
The prevalence of hypertension at 58% is similar to 
data from all European registries. The exception is again 
American population, where hypertension is present in 
about 75% of people. This is obviously related to a higher 
prevalence of obesity in US society compared to Western 
Europe or Poland.
A similar pattern is observed regarding the preva-
lence of type 2 diabetes. Its frequency, due to the epi-
demic of obesity, is markedly higher in the US (40– 
–44%) compared with the Polish population presen-
ted in our study (29%) or the French registry (27%). 
As showed by all registries, atrial fibrillation affects about 
38–40% of patients hospitalized due to HF and is, along 
with hypertension, the major comorbid condition accom-
panying HFpEF.
It is also wor th noting that the propor tion of 
HFpEF patients hospitalized in recent years has gra-
dually increased. Since many hospital records do not 
show LVEF values, we still do not have reliable epide-
miological data on the actual HfrEF/HFpEF ratio. 
It seems, however, that this percentage can reach as much 
as 60–65% of hospitalized patients, which is also confir-
med by the presented registry.
Data concerning the occurrence of comorbid conditions, 
such as chronic kidney disease (CKD) or chronic obstructive 
pulmonary disease (COPD), are also comparable between 
various HF registries. For example, the prevalence of CKD 
with GFR < 30 mL/min/1.73 m2 is 17% in the presented 
registry vs 20% in global registries [12]. The prevalence of 
COPD (16%) is consistent with both OPTIMIZE-HF (15%) [6] 
and European EHFS II (19%) [8].
Conclusions
New registry trials have been emerging over recent years. 
The data collected in these databases provide an excellent 
source of information both for the medical professionals 
and for healthcare system managers. Cardiovascular 
societies continuously update the guidelines for the diag-
nosis and treatment of HF – both considering the results 
of clinical trials, in which the patient population is selec-
ted and unrealistic due to strict criteria for inclusion and 
exclusion, and analyzing clinical practice based on registry 
data. The study presented above proves that the clinical 
profile of Polish patients is very similar to that of patients 
in developed countries. For a practitioner, this means that 
recommendations in the guidelines of the European Society 
of Cardiology can and should be directly implemented in 
the treatment of Polish patients.
Conflict of interest(s)
None declared.
Streszczenie
Wstęp. Niewydolność serca (HF) stanowi poważny problem współczesnej medycyny. Choroba charakteryzuje się wysoką 
śmiertelnością, a rosnąca liczba chorych pociąga za sobą wysokie koszty ochrony zdrowia.
Materiał i metody. W niniejszej pracy oceniono profil kliniczny 100 pacjentów hospitalizowanych w pierwszym kwartale 
2015 roku na oddziale kardiologicznym szpitala powiatowego.
Wyniki. Średni wiek chorych wynosił 73 lata (63% mężczyzn). Najczęstszymi chorobami towarzyszącymi były: nadciśnie-
nie tętnicze (58%), choroba wieńcowa (46%), umiarkowana wada mitralna lub aortalna (34%), migotanie przedsionków 
(38%), cukrzyca (29%).
Wnioski. Dane z rejestrów są pomocne zarówno dla środowiska lekarskiego, jak i zarządzających służbą zdrowia.
Słowa kluczowe: niewydolność serca, hospitalizacja, rejestr
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